George K. Papadimas

Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial

Benedikt Schoser, Mark Roberts, Barry J. Byrne et al. · The Lancet Neurology · 2021 · 124 citations

Clinical Trials, Cipaglucosidase Alfa, Pharmacotherapy +2

Effects of high‐intensity interval cycling performed after resistance training on muscle strength and hypertrophy

Stavroula Tsitkanou, K. Spengos, Angeliki-Nikoletta Stasinaki et al. · Scandinavian Journal of Medicine and Science in Sports · 2016 · 64 citations

Physical Activity, Neuromuscular Coordination, Muscle Function +26

Elevated Muscle-Specific miRNAs in Serum of Myotonic Dystrophy Patients Relate to Muscle Disease Progress

Andrie Koutsoulidou, Tassos C. Kyriakides, George K. Papadimas et al. · PLoS ONE · 2015 · 63 citations · Full text

Effect of aerobic and resistance exercise training on late-onset Pompe disease patients receiving enzyme replacement therapy

Gerasimos Terzis, Filippos Dimopoulos, George K. Papadimas et al. · Molecular Genetics and Metabolism · 2011 · 57 citations

Physical Activity, Enzyme Replacement Therapy, Exercise +11

Effect of serotonin receptor 2 blockage on liver regeneration after partial hepatectomy in the rat liver

George K. Papadimas, Konstantinos Tzirogiannis, Georgios I. Panoutsopoulos et al. · Liver International · 2006 · 51 citations